The Patch should remain available despite health risks, says FDA

A panel of federal health advisers met on Friday to review the safety of the birth control patch.  The patch– known as OrthoEvra and manufactured by Johnson & Johnson– is thought to carry a higher risk of blood clots than other hormonal birth control methods.  However, the federal panel ruled that its benefits outweigh its risks, and suggested it remain available as an option for females who have trouble taking a daily pill.

Read the whole article here.